Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase II study with cetuximab (Erbitux) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck.

Trial Profile

Randomised phase II study with cetuximab (Erbitux) in combination with 5-FU and cisplatin or carboplatin versus cetuximab (Erbitux) in combination with paclitaxel and carboplatin for treatment of patients with relapsed or metastatic squamous cell carcinoma of the head and neck.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms CETMET
  • Most Recent Events

    • 05 May 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.
    • 07 Sep 2020 This trial has been completed in Denmark, according to European Clinical Trials Database record.
    • 05 Jun 2018 Results evaluating efficacy and safety of cetuximab (n=85) were presented at the 54th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top